Literature DB >> 15624042

Immunohistochemical analysis of survivin expression in primary breast cancers.

Jan-Show Chu1, Jin-Yuh Shew, Chiun-Sheng Huang.   

Abstract

BACKGROUND AND
PURPOSE: Survivin, an inhibitor of apoptosis, is expressed in fetal tissues but undetectable in normal adult tissues. It is also expressed in most common human cancers. This study evaluated the expression of survivin in breast cancers.
METHODS: A monoclonal anti-survivin antibody B1 was generated. Immunohistochemical staining was performed in 226 paraffin sections of primary breast cancers and correlated with the patients' clinicopathological characteristics.
RESULTS: Survivin was expressed in the cytoplasm of tumor cells in 59.3% of breast cancers. Expression of survivin was associated with high histologic grade (p = 0.027), high mitotic count (p = 0.014), positive p53 immunostaining (p = 0.012), neu overexpression (p = 0.018), and with bcl-2 (p = 0.001) and bak (p < 0.001) expression. No correlation was found between survivin expression and age, tumor size, estrogen receptor, progesterone receptor or Bax expression. Survivin expression was not significantly associated with overall or disease-free survival.
CONCLUSIONS: Survivin expression is correlated with high histologic grade, high mitotic count, p53 overexpression, and bcl-2 expression in breast cancer. It does not have significance as a marker in predicting overall or disease-free survival.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15624042

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  12 in total

1.  Prognostic value of proliferation markers expression in breast cancer.

Authors:  Natalija Dedić Plavetić; Jasminka Jakić-Razumović; Ana Kulić; Damir Vrbanec
Journal:  Med Oncol       Date:  2013-03-07       Impact factor: 3.064

2.  The role of survivin in diagnosis, prognosis and treatment of breast cancer.

Authors:  Yong-Gang Lv; Fang Yu; Qing Yao; Jiang-Hao Chen; Ling Wang
Journal:  J Thorac Dis       Date:  2010-06       Impact factor: 2.895

3.  Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer.

Authors:  Donal J Brennan; Elton Rexhepaj; Sallyann L O'Brien; Elaine McSherry; Darran P O'Connor; Ailís Fagan; Aedín C Culhane; Desmond G Higgins; Karin Jirstrom; Robert C Millikan; Goran Landberg; Michael J Duffy; Stephen M Hewitt; William M Gallagher
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

4.  Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.

Authors:  Elton Rexhepaj; Karin Jirstrom; Darran P O'Connor; Sallyann L O'Brien; Goran Landberg; Michael J Duffy; Donal J Brennan; William M Gallagher
Journal:  BMC Cancer       Date:  2010-11-23       Impact factor: 4.430

5.  p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors.

Authors:  Roberta Soares Faccion; Paula Sabbo Bernardo; Giselle Pinto Faria de Lopes; Leonardo Soares Bastos; Cristina Lordello Teixeira; José Antonio de Oliveira; Priscila Valverde Fernandes; Luiz Gustavo Dubois; Leila Chimelli; Raquel Ciuvalschi Maia
Journal:  Cell Oncol (Dordr)       Date:  2018-01-26       Impact factor: 6.730

6.  Role of traditional and new biomarkers in breast carcinogenesis.

Authors:  D Macis; M Cazzaniga; A De Censi; B Bonanni
Journal:  Ecancermedicalscience       Date:  2009-10-29

7.  Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence.

Authors:  N Barnes; P Haywood; P Flint; W F Knox; N J Bundred
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

8.  Survivin regulation by HER2 through NF-κB and c-myc in irradiated breast cancer cells.

Authors:  Vassilis Papanikolaou; Dimitrios Iliopoulos; Ioannis Dimou; Stephanie Dubos; Constantine Kappas; Sofia Kitsiou-Tzeli; Aspasia Tsezou
Journal:  J Cell Mol Med       Date:  2011-07       Impact factor: 5.310

9.  Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study.

Authors:  Sarah Adel Hakim; Hoda Hassan Abou Gabal
Journal:  Pathol Oncol Res       Date:  2021-04-09       Impact factor: 3.201

10.  Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion.

Authors:  Yasuhiro Okumura; Yutaka Yamamoto; Zhenhuan Zhang; Tatsuya Toyama; Teru Kawasoe; Mutsuko Ibusuki; Yumi Honda; Ken-ichi Iyama; Hiroko Yamashita; Hirotaka Iwase
Journal:  BMC Cancer       Date:  2008-10-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.